EUVIMEDEUVIMED entdecken
Open Access

Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma

Zhou Zhang, Benjamin Derman iD, Bei Wang iD, Krissana Kowitwanich, John Cursio iD, Lu Gao iD, Daniel Appelbaum iD, Chuan He, Andrzej Jakubowiak iD, Wei Zhang iD, Brian C Chiu iD

JCO Precision Oncology · 2026-07 · 10 (7)

DOI: 10.1200/po-25-01121 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2026-07. Verfasst von Zhou Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL. Hauptthemen laut MEDLINE: 5-Methylcytosine, Multiple Myeloma, Cell-Free Nucleic Acids. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIMHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE While survival outcomes in multiple myeloma (MM) have improved with contemporary combination therapies, predicting disease trajectories for individual patients at diagnosis remains a significant challenge. We investigate the prognostic value of a noninvasive biomarker—cell-free DNA (cfDNA)‑derived 5-hydroxymethylcytosine (5hmC) signature—in newly diagnosed MM, aiming to improve risk stratification at diagnosis. MATERIALS AND METHODS In this prospective cohort study, 321 patients with newly diagnosed MM were enrolled between 2010 and 2017, with follow-up through 2022. We profiled genome-wide 5hmC modifications (gene bodies) in cfDNA collected at diagnosis. We applied elastic net regularization to a Cox proportional hazards model to identify 5hmC signatures associated with overall survival (OS) and progression-free survival (PFS). A weighted prognostic score (wp-score), based on 18 key 5hmC-modified genes, was developed through machine learning and validated in the validation set, controlling for clinical prognostic factors. RESULTS During a median follow-up of 70.5 months, 127 deaths occurred. The cfDNA 5hmC at diagnosis reflected the 5hmC in bone marrow‑derived tumor cells and differed across clinical subgroups. The wp-score showed strong prognostic ability for OS (hazard ratio [HR], 2.9 [95% CI, 1.7 to 4.9]; P < .0001) and PFS (HR, 1.8 [95% CI, 1.3 to 2.5] P = .00014) in the validation set, controlling for known prognostic factors, including stage, lactate dehydrogenase levels, and treatment type. The wp-score calculated at diagnosis remained associated with OS and PFS at 24-, 48-, and 72-month follow-up periods. CONCLUSION This prospective study suggests that cfDNA-derived 5hmC signatures at diagnosis provide independent prognostic information for OS and PFS in MM. These findings support further investigation and independent validation of noninvasive epigenomic biomarkers within contemporary MM risk stratification frameworks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

5-MethylcytosineMultiple MyelomaCell-Free Nucleic AcidsHumansPrognosisProspective StudiesFemaleMaleAgedBiomarkers, Tumor

Substanzen

5-Methylcytosine5-hydroxymethylcytosineCell-Free Nucleic AcidsBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.
  • Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL.
  • Department of Public Health Sciences, The University of Chicago, Chicago, IL.
  • Department of Chemistry, The University of Chicago, Chicago, IL.
  • Department of Radiology, The University of Chicago, Chicago, IL.
  • Department of Biochemistry and Molecular Biology, Institute for Biophysical Dynamics and Howard Hughes Medical Institute, The University of Chicago, Chicago, IL.

ORCID-Profile: Benjamin Derman, Bei Wang, John Cursio, Lu Gao, Daniel Appelbaum, Andrzej Jakubowiak, Wei Zhang, Brian C Chiu

Förderung

  • NCI NIH HHS
  • NIMHD NIH HHS

Zitieren

APA

Zhang, Z., Derman, B., Wang, B., Kowitwanich, K., Cursio, J., Gao, L., Appelbaum, D., He, C., Jakubowiak, A., Zhang, W., & Chiu, B. C. (2026). Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma. JCO Precision Oncology, 10(7). https://doi.org/10.1200/po-25-01121

Vancouver

Zhang Z, Derman B, Wang B, Kowitwanich K, Cursio J, Gao L, et al. Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma. JCO Precision Oncology. 2026;10(7). doi:10.1200/po-25-01121

BibTeX
@article{Zhang2026,
  author = {Zhang, Zhou and Derman, Benjamin and Wang, Bei and Kowitwanich, Krissana and Cursio, John and Gao, Lu and Appelbaum, Daniel and He, Chuan and Jakubowiak, Andrzej and Zhang, Wei and Chiu, Brian C},
  title = {Prognostic Significance of Cell-Free DNA Derived 5-Hydroxymethylcytosine Signatures in Newly Diagnosed Multiple Myeloma},
  journal = {JCO Precision Oncology},
  year = {2026},
  volume = {10},
  number = {7},
  doi = {10.1200/po-25-01121}
}
Kostenlos starten →